Phase I/II study of immunization with multiple peptides mixed with the immunological adjuvant CpG 7909 in HLA-A2 patients with metastatic melanoma LUD 03-007 - LUD 03-007

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-004686-15-DE

Enrollment

Registered

2005-01-18

Start date

2005-08-04

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HLA-A2 patients with metastatic melanoma

Interventions

Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: CpG 7909 Concentration number: see protocoll- INN or Proposed INN: MAGE-1.A2 INN or Proposed INN: MAGE-3.A2 INN or Proposed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: standard inclusion criteria, see protocoll Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: standard exclusion criteria, see protocoll

Design outcomes

Primary

Measure	Time frame
Main Objective: see protocoll;Secondary Objective: see protocoll;Primary end point(s): CTL Response: MLPC/Tetramer Cloning Essay	—

Countries

Germany

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026